Controlled ovarian hyperstimulation regimens: a review of the available evidence for clinical practice. Produced on behalf of the BFS Policy and Practice Committee

Nardo LG, L. G. Nardo, Luciano G. Nardo, E Bosch, Ernesto Bosch, Bosch E, C B Lambalk, Cornelis B. Lambalk, Tarek A. Gelbaya, Gelbaya TA, T. A. Gelbaya
Human fertility (Cambridge, England) · 2013 · vol. 16(3) , pp. 144–150 · doi:10.3109/14647273.2013.795385 · PMID:23705667 · W2147085561
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This review discusses evidence for selecting controlled ovarian hyperstimulation protocols based on patient factors, finding the long GnRH agonist protocol preferred for unselected populations and GnRH antagonist for high responders, while noting limited evidence for poor responders.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Before planning an assisted conception treatment cycle, a thorough assessment of the woman's hormone profile and ovarian reserve is essential to aid the decision on the appropriate protocol for controlled ovarian hyperstimulation (COH). There is insufficient evidence to recommend the use of one type of gonadotrophins over another. There is no benefit of luteinising hormone (LH) supplementation in cycles stimulated with follicle stimulating hormone alone in an unselected population. There is some evidence to suggest a potential benefit of LH supplementation in patients with a history of poor ovarian response to stimulation and in those older than 35 years. The long gonadotrophin releasing hormone (GnRH) agonist protocol is the most widely used and is the preferred protocol in the unselected population of women undergoing COH for in vitro fertilisation or intra-cytoplasmic sperm injection. The GnRH antagonist protocol is best used for known or suspected high responders, including women with PCOS, as it reduces the risk of OHSS. There is a lack of robust evidence to suggest that the GnRH agonist protocol is better than the GnRH antagonist protocol in poor responders. The prolonged GnRH agonist protocol is advantageous in women who are undergoing COH due to pelvic endometriosis. Oral contraceptive pill pre-treatment adversely affects the IVF outcome in GnRH antagonist cycles, but not in GnRH agonist cycles.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Evidence-Based Medicine Ovarian Hyperstimulation Syndrome Ovulation Induction Practice Guidelines as Topic Female Fertility Fertility Agents, Female Fertility Agents, Female Fertilization in Vitro Humans Infertility, Female Infertility, Female Ovarian Hyperstimulation Syndrome Ovulation Induction Ovulation Induction Societies, Scientific United Kingdom

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (69)

Source provenance

europepmc
last seen: 2026-09-07T06:12:11.729357+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:59.468224+00:00
unpaywall
last seen: 2026-09-07T06:27:18.705824+00:00
License: CC0 · commercial use OK